{"id":"W4391506607","doi":"10.1016/j.esmoop.2023.102226","title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bayer Yakuhin; Sierra Oncology; Eli Lilly Japan; Pfizer Japan; Novartis Pharma; INCLIVA Instituto de Investigación Sanitaria; Ipsen; Teijin Pharma; Japanese Society of Medical Oncology; Otsuka Pharmaceutical; Daiichi Sankyo Europe; Veracyte; European Society for Medical Oncology; Chugai Pharmaceutical; Vifor Pharma; Natera; Daiichi-Sankyo; MacroGenics; AstraZeneca; Genentech; Sysmex Corporation; Astellas Pharma; Eisai; FibroGen; Fondazione Beretta; BeiGene; Mirati Therapeutics; Hellenic Society of Medical Oncology; Pharmacyclics; Exelixis; Kissei; Pfizer; American Association for Cancer Research; Servier; Incyte; JST-Mirai Program; Astellas Foundation for Research on Metabolic Disorders; Gilead Sciences; Taiho Pharmaceutical; Boehringer Ingelheim Japan; Merck KGaA; Sanofi; Amgen; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; SymBio Pharmaceuticals Limited; American Society of Clinical Oncology; Foundation Medicine; GlaxoSmithKline; Seagen; Relay Therapeutics","keywords":"Medicine; Cancer; Clinical Practice; Intensive care medicine; Internal medicine; Oncology; Family medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003719024,0.0001507243,0.0003480564,0.0000567639,0.00006917728,0.00007678325,0.0001530605,0.00004065164,0.000126579],"category_scores_gemma":[0.0005809834,0.00007750784,0.00009329642,0.000235121,0.0000525979,0.0001756203,0.0001108061,0.0000769384,0.000003394733],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006757099,"about_ca_system_score_gemma":0.0001774061,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003759044,"about_ca_topic_score_gemma":0.001355485,"domain_scores_codex":[0.9989087,0.00003248467,0.0004044152,0.0002921245,0.0001934491,0.0001688197],"domain_scores_gemma":[0.9985878,0.0006175149,0.0001272353,0.000264678,0.0003342038,0.00006856331],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001182192,0.0001960553,0.4440404,0.00006566556,0.0009936272,0.00001017837,0.0001709559,0.00000308708,9.751032e-8,0.000134851,0.09527354,0.4579293],"study_design_scores_gemma":[0.004649275,0.001130443,0.4701901,0.0001558128,0.001446676,0.000001920401,0.000320193,0.0001110238,0.000006834371,0.00001137162,0.5219094,0.00006699208],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5723149,0.02098374,0.002326317,0.3604773,0.006161739,0.02608119,0.0005964942,0.000246526,0.01081185],"genre_scores_gemma":[0.9639586,0.009921649,0.009386094,0.004467464,0.00059465,0.00186124,0.0001225121,0.00006403832,0.009623772],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4578623,"threshold_uncertainty_score":0.5682575,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1231281084762858,"score_gpt":0.4420520611936647,"score_spread":0.3189239527173789,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}